SOLID LIPID NANOPARTICLE: A NOVEL APPROACH IN DRUG DELIVERY SYSTEM

[1]Debraj De*, [2]Priyanka Ghosh and [3]Rabindranath Pal

[1]M.Pharm (Pharmaceutics), College: Calcutta Institute of Pharmaceutical Technology & Allied Health Sciences, Uluberia, Howrah, 711316.

[2]M.Pharm (Pharmaceutics), College: Calcutta Institute of Pharmaceutical Technology & Allied Health Sciences, Uluberia, Howrah, 711316.

[3]Associate Professor, Department Of Pharmaceutics, Calcutta Institute Of Pharmaceutical Technology & Allied Health Sciences, Uluberia, Howrah.

*Corresponding Author
Mr. Debraj De

M.Pharm (Pharmaceutics), College: Calcutta Institute of Pharmaceutical Technology & Allied Health Sciences, Uluberia, Howrah, 711316.

ABSTRACT

Solid lipid nanoparticles are at the forefront of the rapidly developing field of nanotechnology with several potential applications in drug delivery, clinical medicine and research as well as in other varied sciences. Solid lipid nanoparticle (SLN) dispersions have been proposed as a new type of colloidal drug carrier system suitable for intravenous administration. The system consists of spherical solid lipid particles in the nanometer ranges, which are dispersed in water or in aqueous surfactant solution. It is identical to an oil-in-water emulsion for parenteral nutrition but the liquid lipid (oil) of the emulsion has been replaced by a solid lipid, i.e., yielding Solid Lipid Nanoparticles. Different production methods which are suitable for large scale production and applications of solid lipid nanoparticles are described. Appropriate analytical techniques for characterization of solid lipid nanoparticles like photon correlation spectroscopy, scanning electron microscopy, differential scanning calorimetry are highlighted. Aspects of solid lipid nanoparticles route of administration and their biodistribution are also incorporated. If appropriately investigated, solid lipid nanoparticles may open new vistas in therapy of complex diseases.

KEYWORDS: Solid lipid nanoparticles (SLN), colloidal drug carriers, homogenization, TEM, PCS, biodistribution, targeting.

I. INTRODUCTION

Colloidal particles ranging in size between 10 and 1000 nm are known as nanoparticles. They are manufactured from synthetic/natural polymers and ideally suited to optimize drug delivery and reduce toxicity. Over the years, they have emerged as a variable substitute to liposomes as drug carriers. The successful implementation of nanoparticles for drug delivery depends on their ability to penetrate through several anatomical barriers, sustained release of their contents and their stability in the nanometer size. However, the scarcity of safe polymers with regulatory approval and their high cost have limited the wide spread application of nanoparticles to clinical medicine.[1] To overcome these limitations of polymeric nanoparticles, lipids have been put forward as an alternative carrier, particularly for lipophilic pharmaceuticals. These lipid nanoparticles are known as solid lipid nanoparticles (SLNs), which are attracting wide attention of formulators world-wide.[2] SLNs are colloidal carriers developed in the last decade as an alternative system to the existing traditional carriers (emulsions, liposomes and polymeric nanoparticles). They are a 3 new generation of submicron-sized lipid emulsions where the liquid lipid (oil) has been substituted by a solid lipid. SLN offer unique properties such as small size, large surface area, high drug loading and the interaction of phases at the interfaces, and are attractive for their potential to improve performance of pharmaceuticals, neutraceuticals and other materials.[3] SLNs are attracting major attention as novel colloidal drug carrier for intravenous applications.[1] The SLNs are sub-micron colloidal carrier which is composed of physiological lipid, dispersed in water or in an aqueous surfactant solution. The Pubmed search till the date indicates the trends in SLN research, given in fig. 1. So if systematically investigated, SLNs may open new vista in research and therapy.[4]

Sr. No.	Property	SLN	Polymer Nanoparticles	Liposomes	Lipid Emulsions
1	Systemic toxicity	Low	> or = to SLN	Low	Low
2	Cytotoxicity	Low	> = to SLN	Low	Low
3	Residues from organic solvents	No	Yes	May or may not	No
4	Large scale production	Yes	No	Yes	Yes
5	Sterilization by autoclaving	Yes	No	No	Yes
6	Sustained release	Yes	Yes	< or = to SLN	No
7	Avoidance of RES	Depend on size and coating	No	Yes	Yes

Comparative properties of solid lipid nanoparticles, Polymeric nanoparticles, Liposomes, Lipid emulsions

1.1 Advantages of SLN

1. SLNs have better stability and ease of upgradability to production scale as compared to liposome.

2. In SLNs the lipid matrix is made from physiological lipid which decreases the danger of acute and chronic toxicity.

3. Very high long-term stability.

4. It is easy to manufacture than bipolymeric nanoparticles.

5. Better control over release kinetics of encapsulated compound.

6. SLNs can be enhancing the bioavailability of entrapped bioactive.

7. Chemical protection of labile incorporated compound.

8. Raw material which are to be required are same as that of emulsion.

9. Large scale production is possible.

10. High concentration of functional compound can be achieved.

11. Lyophilization possible.

1.2 Disadvantage

1. Poor drug loading capacity. 2. Drug expulsion after polymeric transition during storage. 3. Relatively high water content of the dispersions (70-99.9%). 4. The low capacity to load hydrophilic drugs due to partitioning effects during the production process.

II. Methods of Preparation of Solid Lipid Nanoparticles

2.1.1 Hot homogenization technique

Melting of the lipid

Dissolution of the drug in the melted lipid

Mixing of the preheated dispersion medium and drug lipid melt

Premix using a stirrer to form a coarse pre-emulsion

High pressure homogenization at a temperature above the lipid melting point

O/W – nano emulsion

Solidification of the nano-emulsion by cooling down to room Temperature to form SLN

The drug is dissolved or dispersed in melted solid lipid for SLN or in a mixture of liquid lipid (oil) and melted solid lipid for nanostructure lipid carrier. In the hot homogenization method the lipid melt containing drug is dispersed in a solution of the hot surfactant at same temperature (5–10 0C above the melting point of the solid lipid or lipid blend) by high speed stirring. This pre-emulsion is then passed through a high pressure homogenizer adjusted to the same temperature generally applying three cycles at 500 bar or two cycles at 800 bars. The hot homogenization technique can be used for lipophilic and insoluble drugs. As the exposure time to high temperature is relatively short, many heat sensitive drugs can be safely processed. The technique is not suitable for incorporation of hydrophilic drugs into SLN because higher portion of drugs in water during homogenization results in low entrapment efficiency.[5,6]

2.1.2. Cold homogenization technique Melting of the lipid Dissolution /solubilization of the drug in the melted lipid Solidification of the drug loaded lipid in liquid nitrogen or dry ice.

Grinding in a powder mill (50-100 micrometer particles) Dispersion of the lipid in the cold aqueous dispersion medium Solid lipid nanoparticles The first step of preparation is same as hot homogenization which includes dispersion or dissolving or solubilisation of the drug in the melted lipid. Then the drug lipid mixture is rapidlycooled either by means of liquid nitrogen or dry ice. The drug containing solid lipid is milled by means of mortar or ball mill to micron size (50-100 micron) and these micro particles are dispersed in chilled emulsifier solution yielding a pre-suspension. Then this pre-suspension is subjected to high pressure homogenization at room or below room temperature, where the cavitation force is strong enough to break the micro particles to SLNs. This process avoids or minimizes the melting of lipid and therefore minimizing loss of hydrophilic drug to aqueous phase. Another method to minimize the loss of hydrophilic drug to aqueous phase is to replace water with other media (e.g. oil or PEG 600) with low solubility for the drug. In comparison to hot homogenization, in cold homogenization particle size and polydispersity indexare more. The cold homogenization only minimizes the thermal exposure of drug, but it does notavoid completely it due to melting of the lipid/drug mixture in the first step of preparation.[7] High pressure homogenization increases the temperature of the sample (e.g. 10-20ºC for each homogenization cycle). In most of the cases, 3-5 homogenization cycles at 500-1500 bar are sufficient to prepare SLN. Increasing the number of homogenization cycle or the homogenization pressure resulted in increase of particle size due to particle coalescence whichresulted from high kinetic energy of particles.

Advantages

☐ Low capital cost.

☐ Demonstrated at lab scale.

Disadvantages

☐ Energy intensive process.

☐ Demonstrated at lab scale bimolecular damage.

☐ Polydisperse distributions.

☐ Unproven scalability.

2.2 Ultrasonication or High Speed Homogenization

This ultrasonication technique is a dispersing technique, which was initially used for the production of solid lipid nanodispersion. Ultrasonication based on the mechanism of cavitation. In first step, the drug was added to previously melt solid lipid. In second step, theheated aqueous phase (heated to same temperature) was added to the melted lipid and emulsifiedby probe sonication or by using high speed stirrer or aqueous phase added to lipid phase drop by drop followed by magnetic stirring. The obtained pre-emulsion was ultrasonicated usingprobe sonicator with water bath (at 0ºC). In order to prevent recrystalization during the process, the production temperature kept at least 5ºC above the lipid melting point. The obtainednanoemulsion (o/w) was filtered through a 0.45μm membrane in order to remove impurities carried in during ultrasonication.[8] Then they obtained SLN is stored at 4ºC. To increase the stability of the formulation, was lyophilized by a lyophilizer to obtain freeze-dried powder and sometime mannitol (5%) was added into SLNs as cryoprotector.

Advantages

☐ Reduced shear stress.

Disadvantages

☐ Potential metal contamination.

☐ Physical instability like particle growth upon storage.

2.3 Solvent emulsification-evaporation technique In solvent emulsification-evaporation method, the lipophilic material and hydrophobic drug were dissolved in a water immiscible organic solvent (e.g. cyclohexane, dichloromethane, toluene, chloroform) and then that is emulsified in an aqueous phase using high speed homogenizer. To improve the efficiency of fine emulsification, the coarse emulsion was immediately passed through the micro fluidizer. Thereafter, the organic solvent was evaporatedby mechanical stirring at room temperature and reduced pressure (e.g. rotary evaporator) leavinglipid precipitates of SLNs.[9] Here the

mean particle size depends on the concentration of lipid in organic phase. Very small particle size could be obtained with low lipidload (5%) related to organic solvent. Drug + lipid are dissolvedin H2O immiscible solvent.

Emulsification In aqueous phase O/w emulsion
Solvent evaporation at room temperature and reduced pressure SLN

Advantages

☐ Scalable.

☐ Mature technology.

☐ Continuous process.

☐ Commercially demonstrated.

Disadvantages

☐ Extremely energy intensive process.

☐ Polydisperse distributions.

☐ Bimolecular damage.

2.4. Solvent emulsification-diffusion technique In solvent emulsification-diffusion technique, the solvent used (e.g. benzyl alcohol, butyl lactate, ethyl acetate, isopropyl acetate, methyl acetate) must be partially miscible with water and this technique can be carried out either in aqueous phase or in oil. Initially, both the solvent and water were mutually saturated in order to ensure the initial the rmodynamicequilibrium of both liquid. When heating is required to solubilize the lipid, the saturation step was performed at that temperature. Then the lipid and drug were dissolved in water saturated solvent and this organic phase (internal phase) was emulsified with solvent saturatedaqueous solution containing stabilizer (dispersed phase) using mechanical stirrer. After the formation of o/w emulsion, water (dilution medium) in typical ratio ranges from 1:5 to 1:10, were added to the system in order to allow solvent diffusion into the continuous phase, thus forming aggregation of the lipid in the nanoparticles. Here the both the phase were maintain at same elevated temperature and the diffusion step was performed either at room temperature or at the temperature under which the lipid was dissolved. Throughout the process constant stirring was maintained. Finally, the diffused solvent was eliminated by vacuum distillation or lyophilization.[7] Solvent + Water are mutually saturated.

Add drug and lipid emulsion

o /w emulsion+ Dilution media (water) in the ratio 1:5 - 1:10 Diffusion of solvent to continuous phase.


Table 1

Particle Types:	Solid-Lipid	Polymeric (PLGA)	Liposomes	LyoCell®
Efficiency / Location of Formulated Drug:				
Hydrophobic Molecules	++++ / interior of particle	+++ / interior of particle	+ / in lipid bilayer	+++ / in lipid phase
Hydrophilic Molecules	+ / on particle surface, & possibly entraped in solid-lipids using proprietary technology	+ / on particle surface & possibly entraped in polymer using some processes	++ / in aqueous core of liposomes	++ / in aqueous phase of LyoCells
Amphiphilic Molecules	++ / on particle surface	+ / on particle surfaces	+ / in lipid bilayer	++ / in lipid and aqueous phases
Stability of Aqueous Suspensions	++++	–	++	+++

NANOPARTICLE TYPES AND MAJOR ATTRIBUTES

2.5 Micro emulsion based method This method is based on the dilution of micro emulsions. As micro-emulsions are two-phase systems composed of an inner and outer phase (e.g. o/w micro emulsions). They are made by stirring an optically transparent mixture at 65-70°C, which typically composed of a low melting fatty acid (e.g. stearic acid), an emulsifier (e.g. polysorbate 20), co-emulsifiers (e.g. butanol) and water. The hot micro emulsion is dispersed in cold water (2-3°C) under stirring. SLN dispersion can be used as granulation fluid for transferring in to solid product (tablets, pellets) by granulation process, but in case of low particle content too much of water needs to be removed. High-temperature gradients facilitate rapid lipid crystallization and prevent aggregation. Due to the dilution step; achievable lipid

contents are considerably lower compared with the HPH based formulations.[4] Melting of lipid.

Add aqueous solution of drug to melted lipid

Add Surfactant and co-surfactant at a temperature above the melting point of lipid

Formation of clear w/o micro emulsion Formed w/o micro emulsion is added to a mixture of water, surfactant and co-surfactant under mechanical stirring

Formation of suspension of lipid particles

☐ Wash with dispersion medium by ultrafiltration system

Solid lipid nanoparticles

Advantages

☐ Low mechanical energy input.

☐ Theoretical stability.

Disadvantages

☐ Extremely sensitive to change.

☐ Labor intensive formulation work.

☐ Low nanoparticle concentrations.

2.6 Supercritical fluid technology This is a novel technique which recently applied for the production of SLNs. A fluid is qualifiedas supercritical when its pressure and temperature exceed their respective critical value. Above the critical temperature, it is not possible to liquefy a gas by increasing the pressure. The supercritical fluid has unique thermo-physical properties. As the pressure is raised, the density of the gas increases without significant increase in viscosity while the ability of the fluid to dissolve compounds also increases. A gas may have little to no ability to dissolve a compound under ambient condition can completely dissolve the compound under high pressure in supercritical range. Therefore, its solvation power is altered by careful control of changes in temperature and pressure. Many gases like, CO_2, ammonia, ethane and CH_2FCF_3 were tried, but CO_2 is the best option for SCF technique because, it is generally regarded as safe, easily accessible critical point [31.5ºC, 75.8 bar), does not causes the oxidation of drug material, leaves no traces behind after the process, is inexpensive, noninflammable, environmentally acceptable an easy to recycle or to dispose off. In the SCF phase or this technique generally use organic solvents (e.g. DMSO, DMFA) because they are fully miscible in SCF-CO_2. This technology comprises several

processes for nanoparticles production such as rapid expansion of supercritical solution (RESS), particles from gas saturated solution(PGSS), gas/supercritical anti solvent (GAS/SAS), aerosol solvent extraction solvent (ASES), solution enhanced dispersion by supercritical fluid (SEDS), supercritical fluid extraction of emulsions (SFEE). Mainly SAS and PGSS were used for SLN preparation.[7]

2.6.1 GAS/SAS

In this process SCF acts as antisolvent for processing solid that are insoluble in SCF. It exploits the ability of SCF to dissolve in organic solvent and reduce the solvation power of solid in solution, thus causing the solid to precipitate. At first, the near critical or supercritical fluid was introduced in a vessel containing an organic solvent in which the solid material to be crystallized was dissolved which causes the intimate mixing of the fluid and liquid resulting in liquid expansion and particle precipitation. A clear disadvantage of this technique is the lack of control on the particle formation. A modification of SAS technique was used to prepare lysozyme spherical nanoparticles, which combines both the atomization and anti-solvent process, by using water/ethanol solution.

2.6.2 PGSS In this process, the SCF was dissolved in liquid substrate, or a solution of substrate in solvent, or a suspension of substrate in solvent followed by a rapid depressurization of this mixture through a nozzle causing the formation of SLN. The great advantage of this process is that it produces particles of great variety of substance that need not be soluble in SCF-CO2. Limitations are, care must be taken for thermolabile solute and the final product may contain microparticles. Insulin nanoparticles are produced by this process, in which the solvent used, was DMSO and the lipid mixture (tristearin, phosphatidylcholine, dioctylsulfosuccinate) were atomized to produce insulin SLN (<500nm).

2.7 Double emulsion technique In double emulsion technique the drug (mainly hydrophilic drugs) was dissolved in aqueous solution, and then was emulsified in melted lipid. This primary emulsion was stabilized by adding stabilizer (e.g. gelatin, poloxamer-407). Then this stabilized primary emulsion was dispersed in aqueous phase containing hydrophilic emulsifier (e.g. PVA). Thereafter, the double emulsion was stirred and was isolated by filtration. Double emulsion technique avoids the necessity to melt the lipid for the preparation of peptide-loaded lipid nanoparticles and the surface of the nanoparticles could be modified in order to sterically stabilize them by means of the incorporation of a lipid/-PEG derivative.

Sterical stabilization significantly improved the resistance of these colloidal systems in the gastrointestinal fluids.[10] This technique is mainly used to encapsulate hydrophilic drug (peptides).

2.8 Membrane contactor technique It is a novel technique to prepare the SLN. In membrane contactor technique the liquid phase was pressed at a temperature above the melting point of the lipid through the membrane pores allowing the formation of small droplets as indicated in Figure 2. The aqueous phase was stirred continuously and circulates tangentially inside the membrane module, and sweeps away the droplets being formed at the pore outlets. SLNs were formed by the cooling of the preparation at the roomtemperature. Here both the phases were placed in the thermostated bath to maintain the requiredtemperature and nitrogen was used to create the pressure for the liquid phase. The influence of various process parameters (aqueous phase cross flow velocity, the lipid phasepressure, aqueous and lipid phase temperature, lipid phase amount and membrane pore size) were studied. The membrane contactor method is also used for the preparation of polymeric nanoparticles, by methods involving apolymerization of dispersed monomers (interfacial polymerization method) or a dispersion of preformed polymers (nanoprecipitation method). The advantages of this process of SLN preparation using a membrane contactor are shown to be its facility of use, the control of the SLN size by an appropriate choice of process parameters and it's scaling up ability.[7]

Schematic drawing of the membrane contactor for the SLN preparation

2.9 Solvent injection technique It is based onlipid precipitation from the dissolved lipid in solution. In this technique, the solid lipid was dissolved in water-miscible solvent (e.g. ethanol, acetone, isopropanol) or a water-miscible solvent mixture. Then this lipid solvent mixture was injected through an injection needle in to stirred aqueous phase with or without

surfactant. The resulted dispersion was then filtered with a filter paper in order to remove any excess lipid.

The presence of emulsifier within the aqueous phase helps to produce lipid droplets at the site of injection and stabilize SLN until solvent diffusion was complete by reducing the surface tension between water and solvent resulting in solvent.

Advantages

 use of pharmacologically acceptable organic solvent

 easy handling

 Fast production process without technically sophisticated equipment.

III. Drug release from SLN

There are mainly three drug incorporation models which describe the incorporation of drug into SLN.[7] 1. Homogenous matrix model. 2. Drug enriched shell, core shell model. 3. Drug enriched core, core shell model.

Fig. 3: Models of incorporation of active compounds into SLN.

(a) Homogeneous Matrix,

(b) Drug enriched shell with lipid core,

(c) Drug enriched core with lipid shell.

Homogenous matrix model or solid solution model with drug being present in amorphous clusters or molecularly dispersed is mainly obtained when incorporating highly lipophilic drugs into SLN with using hot homogenization technique or applying cold homogenization method or by avoiding potentially drug solubilizing surfactants. In the cold homogenization technique the drug (in molecularly dispersed form) is dispersed in bulk of melted lipid, then the mechanical force of high pressure homogenization leads to the breakdown of molecular form to nanoparticles and giving rise to homogenous matrix model as shown in Figure 3a. Etomidate SLN represents the homogenization matrix model. The drug enriched shell with core shell model will be obtained when performing the production. During the production, the drug partitioned to water phase. Upon cooling, the lipid precipitates first, forming a practically drug free lipid core due to phase separation. At the same time, the drug re-partitions into the remaining liquid-lipid phase and drug concentration in the outer shell increasing gradually. Finally drug enriched shell crystallizes as depicted in Fig. 3b. The amount of drug partitioning to the aqueous phase will increases with the increase of solubility of drug in the aqueous phase. Mainly two factors, increasing temperature of the aqueous phase and increasing surfactant concentration, are increasing the saturation solubility of drug in water phase. Tetracaine SLN were prepared by hot HPH shows drug enriched shell model. A drug enriched core obtained when dissolving a drug (e.g. prednisolone) in the lipid melts at or close to its saturation solubility. In this model, cooling of the formed nanoemulsion will lead to super saturation of drug in melted lipid and it further leads drug precipitation prior to lipid precipitation. Further cooling will lead to precipitation of lipid surrounding the drug enriched core as a membrane as indicated in Figure 3c. Due to increased diffusional distance and hindering effect of surrounding solid lipid shell, the carrier system shows sustained release profile.

IV. Characterization of SLNS

4.1 Measurement of particle size and zeta potential[4,11,12]

Photon correlation spectroscopy (PCS) and laser diffraction (LD) are the most powerful techniques for routine measurements of particle size. PCS (also known as dynamic light scattering) measures the fluctuation of the intensity of the scattered light which is caused by particle movement. This method covers a size range from a few nanometers to about 3 microns. PCS is a good tool to characterize nanoparticles, but it is not able to detect larger micro particles. Electron Microscopy provides, in contrast to PCS and LD, direct information on the particle shape. The physical stability of optimized SLN dispersed is generally more

than 12 months. ZP measurements allow predictions about the storage stability of colloidal dispersion.

4.1.1 Photon Correlation Spectroscopy (PCS) It is an established method which is based on dynamic scattering of laser light due to Brownian motion of particles in solution/suspension. This method is suitable for the measurement of particles in the range of 3 nm to 3 mm. The PCS device consists of laser source, a sample cell (temperature controlled) and a detector. Photomultiplier is used as detector to detect the scattered light. The PCS diameter is based on the intensity of the light scattering from the particles.

4.1.2 Electron Microscopy Electron Microscopy methods such as Scanning Electron Microscopy (SEM) and Transmission Electron Microscopy (TEM) are used to measure the overall shape and morphology of lipid nanoparticles. It permits the determination of particle size and distributions. SEM uses electrons transmitted from the surface of the sample while TEM uses electrons transmitted through the sample.

4.1.3 Atomic Force Microscopy (AFM) It is an advanced microscopic technique which is applied as a new tool to image the original unchanged shape and surface properties of the particles. AFM measures the force acting between surface of the sample and the tip of the probe, when the probe is kept in close proximity to the sample which results in a spatial resolution of up to 0.01 nm for imaging.

4.2 Determination of Incorporated Drug Amount of drug incorporated in SLNs influences the release characteristics hence it is very important to measure the amount of incorporated drug. The amount of drug encapsulated per unit wt. of nanoparticles is determined after separation of the free drug and solid lipids from the aqueous medium and this separation can be done by ultracentrifugation, centrifugation filtration or gel permeation chromatography. The drug can be assayed by standard analytical technique such as spectrophotometer, a spectroflurophotometry, HPLC or liquid scintillation counting.

4.3 *In vitro* drug release
4.3.1 Dialysis tubing *In vitro* drug release could be achieved using dialysis tubing. The solid lipid nanoparticle dispersionis placed in pre washed dialysis tubing which can be hermetically sealed. The dialysis sac then dialyzed against a suitable dissolution medium at room

temperature; the samples are withdrawn from the dissolution medium at suitable intervals, centrifuged and analyzed for the drug content using a suitable analytical method.

4.3.2 Reverse dialysis In this technique a number of small dialysis sacs containing 1 mL of dissolution medium are placed in SLN dispersion. The SLN's are then displaced into the medium.

4.4 Rheology Rheological measurements of formulations can perform by Brookfield Viscometer, using a suitable spindle number. The viscosity depends on the dispersed lipid content. As the lipid content increases, the flow becomes non-Newtonian from Newtonian.

4.5 Acoustic methods Another ensemble approach, acoustic spectroscopy, measures the attenuation of sound waves as a means of determining size through the fitting of physically relevant equations. In addition, the oscillating electric field generated by the movement of charged particles under the influence of acoustic energy can be detected to provide information on surface charge.

4.6 Nuclear magnetic resonance (NMR) NMR can be used to determine both the size and the qualitative nature of nanoparticles. The selectivity afforded by chemical shift complements the sensitivity to molecular mobility to provide information on the physicochemical status of components within the nanoparticle.

4.7 X-ray diffraction (powder X-ray diffraction) and differential scanning calorimetry (DSC) The geometric scattering of radiation from crystal planes within a solid allow the presence or absence of the former to be determined thus permitting the degree of crystallinity to be assessed. Another method that is a little different from its implementation with bulk materials, DSC can be used to determine the nature and speciation of crystallinity within nanoparticles through the measurement of glass and melting point temperatures and their associated enthalpies.

V. Routes of Administration and Their Biodistribution

The *in vivo* behavior of the SLN particles will mainly depend on the following points: Interactions of the SLN with the biological surroundings including: distribution processes (Adsorption of biological material on the particle surface and desorption of SLN components into to biological surroundings) and enzymatic processes. Various administration routes are.[13,14]

5.1 Parenteral administration Peptide and proteins drugs are usually available for parenteral use in the market. Since their conventional oral administration is not possible due to enzymatic degradation in GI tract. Parenteral application of SLN reduces the possible side effects of drug incorporated with the increased bioavailability. These systems are very suitable for drug targeting.

5.2 Oral administration Controlled release behavior of SLNs is reported to enable the bypass of gastric and intestinaldegradation of the encapsulated drug, and their possible uptake and transport through the intestinal mucosa. However, the assessment of the stability of colloidal carriers in GI fluids is essential in order to predict their suitability for oral administration.

5.3 Rectal administration When rapid pharmacological effect is required, in some circumstances, parenteral or rectal Administration is preferred. This route is used for pediatric patients due to easy application.

5.4 Nasal administration Nasal route is preferred due to its fast absorption and rapid onset of drug action also avoidingdegradation of labile drugs in the GIT and insufficient transport across epithelial cell layers.

5.5 Respiratory delivery Nebulisation of solid lipid particles carrying anti-tubercular drugs, anti-asthmatic drugs and anticancer was observed to be successful in improving drug bioavailability and reducing the dosing frequency for better management of pulmonary action.

5.6 Ocular administration Biocompatibility and muco-adhesive properties of SLN improve their interaction with ocularmucosa and prolong corneal residence time of the drug, with the aim of ocular drug targeting.

5.7 Topical administration SLN are very attractive colloidal carrier systems for skin applications due to their various desirable effects on skin besides the characteristics of a colloidal carrier system. They are well suited for use ondamaged or inflamed skin because they are based on non-irritant and non-toxic lipids.

VI. Application

6.1. Oral SLNs in ant tubercular chemotherapy Ant tubercular drugs such as rifampicin, isonizide, pyrazinamide-loaded SLN systems, were able to decrease the dosing frequency and improve patient compliance.[15] By using the emulsion solvent diffusion technique this anti tubercular drug loaded solid lipid nanoparticles are prepared.

6.2. SLNs for topical use SLNs used for topical application for various drugsuch as anticancer[16], vitamin-A[17], isotretinoin, flurbiprofen.[18] Using glyceryl behenate, vitamin A-loaded nanoparticles can be prepared. This method is useful for the improvement of penetration with sustained release. Theisotretinoin-loaded lipid nanoparticles were formulated for topical delivery of drug. Production of the flurbiprofen-loaded SLN gel for topical application offer a potential advantage of delivering the drug directly to the site of action, which will produce higher tissue concentrations.

VII. SLNS as Cosmeceuticals

The SLNs have been applied in the preparation of sunscreens and as an active carrier agent for molecular sunscreens and UV blockers. SLN and NLCs have proved to be controlled release innovative occlusive topicals. Better localization has been achieved for vitamin A in upper layers of skin with glyceryl behenate SLNs compared to conventional formulations.[19]

7.4 SLNs as gene vector carrier SLN can be used in the gene vector formulation. There are several recent reports of SLN carrying genetic/peptide materials such as DNA, plasmid DNA

and other nucleic acids.[20] The gene transfer was optimized by incorporation of a diametric HIV-1 HAT peptide(TAT 2) into SLN gene vector. The lipid nuclicacid nanoparticles were prepared from a liquidnanophase containing water and a water miscible organic solvent where both lipid and DNA are separately dissolved by removing the organic solvent, stable and homogeneously sizedlipid-nuclic acid nanoparticle (70-100 nm) were formed. It's called genospheres. It is targetedspecific by insertion of an antibody-lipo polymer conjugated in the particle.

7.5 SLNs in breast cancer and lymph node metastases

Mitoxantrone-loaded SLN local injections were formulated to reduce the toxicity and improve the safety and bioavailability of drug.[21] Efficacy of doxorubicin (Dox) has been reported to beenhanced by incorporation in SLNs. In the methodology the Dox was complexed with soybean-oil-based anionic polymer and dispersed together with a lipid in water to form Dox-loaded solid lipid nanoparticles. The system has enhanced its efficacy and reduced breastcancer cells.

7.6 SLNs as a targeted carrier for anticancer drugto solid tumors SLNs have been reported to be useful as drug carriers to treat neoplasm's.[22] Tumour targeting has been achieved with SLNs loaded with drugs like methotrexate[23] and Camptothecin.[24] Tamoxifen an anticancer drug is incorporated in SLN to prolong release of drug after i.v.

7.6 Stealth nanoparticles

These provide a novel and unique drug-delivery system they evade quick clearance by the immune system. Such nanoparticles can target specific cells. Stealth SLNs have been successfully tested in animal models with marker molecules and drugs. Antibody labelled stealth Lipobodies have shown increased delivery to the target tissue in accessible sites.[25]

7.7 SLNs for potential agriculture application Essential oil extracted from *Artemisiaarboreseens* L when incorporated in SLN, were able to reduce the rapid evaporation compared with emulsions and the systems have been usedin agriculture as a suitable carrier of ecologically safe pesticides.[26]

VIII. CONCLUSIONS

SLN as colloidal drug carrier combines the advantage of polymeric nanoparticles, fat emulsions and liposome; due to various advantages, including feasibility of incorporation of

lipophilic and hydrophilic drugs, improved physical stability, low cost, ease of scale-up, and manufacturing. SLNs are prepared by various advanced techniques. The site specific and sustained release effect of drug can better achieved by using SLNs. Nanoparticles have been used extensively for applications in drug discovery, drug delivery, and diagnostics and for many others in medical field. They are relatively novel drug delivery systems, having received primary attention from the early 1990s and future holds great promise for its systematic investigation and exploitation. We can expect many patented dosage forms in the form of SLNs in the future.

REFERENCES

1. P. Ekambaram, A. Abdul hasansathali K. Priyanka, solid lipid nanoparticles: a review *Scientific Reviews Chemical Communications,* 2012; *2(1):* 80-102.

2. C. Shah, V. Shah, U. Upadhyay, solid lipid nanoparticles: a review *current pharma research,* 2011; *1(4):* 351-368.

3. R. Cavalli, M. R. Gasco, P. Chetoni, S. Burgalassi, Solid lipid nanoparticles (SLN) as ocular delivery system for tobramycin. *International Journal Pharm,* 2002; *238*: 241–245.

4. N. K. Jain, Controlled and Novel Drug Delivery 1st Edition, (CBS Publishers and Distributors 1997) 3-28.

5. S.H. Gohla, A. Dingler, Scaling up feasibility of the production of solid lipid nanoparticles (SLN). *Pharmazie,* 2001; *56*: 61-63.

6. C. Schwarz, W. Mehnert, J.S. Lucks, R.H. Müller, Solid lipid nanoparticles (SLN) for controlled drug delivery: I. Production, characterization and sterilization. *Journal of Controlled Relelease,* 1994; *30*: 83-96.

7. P. Rabinarayan, S. Padilama, Production of Solid Lipid Nanoparticles-Drug Loading and Release Mechanism. *Journal of Chemical and Pharmaceutical Research,* 2010; *2(1):* 211-227.

8. T. Eldem, P. Speiser, A. Hincal, Optimization of spray-dried and congealed lipid microparticles and characterization of their surface morphology by scanning electron microscopy. *Pharm Res.,* 1991; *8:* 47-54.

9. B. Siekmann, K. Westesen. Investigations on solid lipid nanoparticles prepared by precipitation in o/w emulsions. *European J. Pharm. Biopharm,* 1996; *43:* 104-109.

10. R. Cortesi, E. Esposito, G. Luca, C.Nastruzzi. Production of lipospheres as carriers for bioactive compounds. *Biomaterials,* 2002; *23*: 2283-2294.

11. S. Pragati, S. Kuldeep, S. Ashok, Solid Lipid Nanoparticles: A Promising Drug Delivery Technology. *International Journal of Pharmaceutical Sciences and Nanotechnology,* 2009; *2(2):* 509-516.

12. S. N. Mistry, P. K. Patel, P. D. Bharadia, V. M. Pandya, D. A. Modi, Novel Drug Delivery System for Lipophilic Agents: Solid Lipid Nanoparticles. *IJPI's Journal of Pharmaceutics and Cosmetology,* 2011; *1(4):* 76-89.

13. S. P. Vyas and R. K. Khar, Controlled Drug Delivery - Concepts and Advances, 1st Edition, (Vallabh Prakashan 2002) 38-50.

14. P. K. Gupta, J. K. Pandit, A. Kumar and P. Swaroop, S.gupta, *T. Ph. Res.,* 2010; *3:* 117-138.

15. R.Pandey, S. Sharma, G.K. Khuller. Oral SLN Based antitubercular chemotherapy, *Tuberculosis (Edinb),* 2005; *85*: 415-420.

16. H. Chen, X. Chang, D. Du, W. Liu, J. Liu, *Podophyllotoxin-* loaded solid lipid nanoparticles for epidermal targeting. *Journal of Control Release,* 2006; *110*: 296-306.

17. V. Jenning, S. Gohla, Vitamin A-loaded solid lipid nanoparticles for topical use: drug release properties. *Journal of Control Release,* 2000; *66*: 115-126.

18. M.C. Santos, W. Mehnert, M. Schaller, Drug targeting by solid lipid nanoparticles for dermal use. *Journal Drug Target,* 2002; *10:* 489-495.

19. S.A. Wissing, R.H. Muller, Solid lipid nanoparticles (SLN) a novel carrier for U V blockers. *Pharmazie,* 2001; *56*: 783-786.

20. C. Rudolph, U. Schillinger, A. Ortiz, K. Tabatt, C. Plank, R.H. Muller, Application of novel Solid lipid nanoparticles (SLN) - gene vector formulations based on a diametric HIV-1 VAT - peptide *in vitro* and *in vivo. Pharmaceutic Res,* 2004; *21*: 1662-1669.

21. B. Lu, S.B. Xiong, H. Yang, X.D. Yin, R.S. Chao, Solid lipid nanoparticles of mitoxantrone for local injection against breast cancer and its lymphnode metastases. *European Journal of Pharm. Sciences,* 2006; *28:* 86-95.

22. V.S. Shenoy, I.K. Vijay, R.S. Murthy. Tumour targeting: Biological factors and formulation advances in injectable lipid nanoparticles. *Journal Pharm Pharmacol,* 2005; *57:* 411-422.

23. K. Ruckmani, M. Sivakumar, P.A. Ganeshkumar, Methotrexate loaded solid lipid nanoparticles (SLN) for effective treatment of carcinoma. *Journal Nano sciences Nanotechnology,* 2006; *6*: 2991-2995.

24. S.C.Yang, L.F.Lu, Y. Cai, J.B. Zhu, B.W. Liang, Body distribution in mice of intravenously injected camptothecin solid lipid nanoparticles and targeting effect on brain. *Journal of Control Release,* 1999; *59*: 299-307.

25. Y. Wang, W. Wu, *In situ* evading of phagocytic uptake of stealth solid lipid nanoparticles by mouse peritoneal macrophages. *Drug Delivery,* 2006; *13:* 189-192.

26. F. Lai, S.A. Wissing, R.H. Muller, A. M. Fadda *Artemisia arborescens* L essential oil-loaded solid lipid nanoparticles for potential agriculture application: Preparation and characterization. *AAPS Pharm Sci Tech,* 2006; *7*: 21-27.

27. Gasco MR. Method for producing solid lipid microspheres having narrow size distribution. United State Patent. USS 188837; 1993.

28. Gasco MR. Solid lipid nanospheres from warm microemulsions. Pharm Tech Eur., 1997; 9: 528.

29. Boltri L, Canal T, Esposito PA, Carli F. Lipid nanoparticles: Evaluation of some critical formulation parameters. Proc Intern Symp Control Rel Bioact Mater, 1993; 20: 346-7.

30. De Labouret A, Thioune O, Fessi H, Devissaguet JP, Puiseieux F. Application of an original process for obtaining colloidal dispersions of some coating polymers. Preparation, Charecterization, industrial scaling up. Drug Develop Ind Pharm, 1995; 21: 229-41.

31. Cavalli R, Marengo E, Rodriguez L, Gasco MR. Effects of some experimental factors on the production process of solid lipid nanoparticles. Eur J Pharm Biopharm, 1996; 43: 110-5.

32. Chen YJ, Jin RX, Zhou YQ, Zeng J, Zhang H, Feng QR. Preparation of solid lipid nanoparticles loaded with Xionggui powder-supercritical carbon dioxide fluid extraction and their evaluation in vitro release. Zhongguo Zhong Yao Za Zhi., 2006; 31: 376-9.

33. Kaiser CS, Rompp H, Schmidt PC. Pharmaceutical applications of supercritical carbon dioxide. Pharmazie, 2001; 56: 907-26.

34. Gosselin PM, Thibert R, Preda M, McMullen JN. Polymeric properties of micronized carbamazepine produced by RESS. Int J Pharm, 2003; 252: 225-33.

35. Freitas C, Mullera RH. Spray-drying of Solid lipid nanoparticles (SLN TM). Eur J Pharm Biopharm, 1998; 46: 145-51.

36. Cortesi R, Esposito E, Luca G, Nastruzzi C. Production of lipospheres as carriers for bioactive compounds. Biomaterials, 2002; 23: 2283-94.

37. Meyer E, Heinzelmann H. Scanning force microscopy. In: Wiesendanger R, Guntherodt HJ. Editors. Scanning tunneling microscopy II, Surface science. New York: Springer Verlag, 1992; 99-149.

38. Drake B, Prater CB, Weisenhorn AL, Gould SAC, Albrecht TR, Quate CF, *et al.* Imaging crystals polymers and process in water with the AFM. Science, 1989; 243: 1586-9.

39. Jannin V, Musakhanian J, Marchaud D. Approach for the development of Solid and semi-solid lipid-based formulations. Adv Drug Deliv Rev., 2008; 60: 734-47.

40. Yang S, Zhu J, Lu Y, Ling B, Yang C. Body distribution of camptothecin solid lipid nanoparticles after oral administration. Pharm Res., 1999; 16: 751-7.

41. Yang SC, Lu LF, Cai Y, Zhu JB, Liang BW, Yang CZ. Body distribution in mice of intravenously injected camptothecin solid lipid nanoparticles and targeting effect on brain. J Control Release, 1999; 59: 299-307.

42. Zur Muhlen A, Mehnert W. Drug release and release mechanism of prednisolone loaded solid lipid nanoparticles. Pharmazie, 1998; 53: 552-5.

43. Prow T, Smith JN, Grebe R, Salazar JH, Wang N, Kotov N, *et al.* Construction, gene delivery, and expression of DNA tethered nanoparticles. Mol Vis., 2006; 12: 606-15.

44. Rudolph C, Schillinger U, Ortiz A, Tabatt K, Plank C, Muller RH, *et al.* Application of novel Solid lipid nanoparticles (SLN)- gene vector formulations based on a diametric HIV-1 VAT –peptide in vitro and in vivo. Pharmaceutic Res., 2004; 21(9): 1662-9.

45. Hayes ME, Drummond DC, Kirpotin DB. Self-assembling nucleic acid-lipid nanoparticles suitable for targeted gene delivery. Gene Ther., 2006; 13: 646-51.

46. Pedersen N, Hansen S, Heydenreich AV, Kristensen HG, Poulsen HS. Solid lipid nanoparticles can effectively bind DNA, streptavidin and biotinylated ligands. Eur J Pharm Biopharm, 2006; 62: 155-62.

47. Mei Z, Wu Q. Triptolide loaded solid lipid nanoparticle hydrogel for topical application. Drug Develop Ind Pharm, 2005; 31: 161-8.

48. Chen H, Chang X, Du D, Liu W, Liu J. Weng T, *et al.* Podophyllotoxin-loaded solid lipid nanoparticles for epidermal targeting. J Control Release, 2006; 110: 296-306.

49. Jenning V, Schafer-Korting M, Gohla S. Vitamin A-loaded solid lipid nanoparticles for topical use: drug release properties. J Control Release, 2000; 66: 115-26.

50. Liu J, Hu W, Chen H, Ni Q, Xu H, Yang X. Isotretinoin-loaded solid lipid nanoparticles with skin targeting for topical delivery. Int J Pharm, 2007; 328: 191-5.

51. Choi MJ, Kim JH, Maibach HI. Topical DNA vaccination with DNA/Lipid based complex. Curr Drug Deliv, 2006; 3: 37-45.

52. Jain SK, Chourasia MK, Masuriha R. Solid lipid nanoparticles bearing flurbiprofen for transdermal delivery. Drug Deliv, 2005; 12: 207-15.

53. Santos MC, Mehnert W, Schaller M. Drug targeting by solid lipid nanoparticles for dermal use.J Drug Target, 2002; 10: 489-95.

54. Wissing SA, Muller RH. Solid lipid nanoparticles (SLN) a novel carrier for UV blockers. Pharmazie, 2001; 56: 783-6.

55. Mei Z, Wu Q. Triptolide loaded solid lipid nanoparticle hydrogel for topical application. Drug Develop Ind Pharm, 2005; 31: 161-8.

56. Wissing S, Lippacher A, Muller R. Investigations on the occlusive properties of solid lipid nanoparticles (SLN). J Cosmet Sci., 2001; 52: 313-24.

57. Jenning V, Gysler A, Schafer-Korting M, Gohla SH. Vitamin A loaded solid lipid nanoparticles for topical use: occlusive properties and drug targeting to the upper skin. Eur J Pharm Bio pharm, 2000; 49: 211-8.

58. Lai F, Wissing SA, Muller RH, Fadda AM. Artemisia arborescens L essential oil-loaded solid lipid nanoparticles for potential agriculture application: preparation and characterization. AAPS Pharm Sci Tech, 2006; 7(1): E2.

59. Shenoy VS, Vijay IK, Murthy RS. Tumour targeting: biological factors and formulation advances in injectable lipid nanoparticles. J Pharm Pharmacol, 2005; 57: 411-22.

60. Murthy RSR. Solid lipid nanoparticles as carriers for anti-cancer drugs to solid tumours. Drug Deliv, 2005; 12: 385-92.

61. Ruckmani K, Sivakumar M, Ganeshkumar PA. Methotrexate loaded solid lipid nanoparticles (SLN) for effective treatment of carcinoma. J Nanosci Nanotechnol, 2006; 6: 2991-5.

62. Yang SC, Lu LF, Cai Y, Zhu JB, Liang BW, Yang CZ. Body distribution in mice of intravenously injected camptothecin solid lipid nanoparticles and targeting effect on brain. J Control Release, 1999; 59: 299-307.

63. Lu B, Xiong SB, Yang H., Yin XD, Chao RB. Solid lipid nanoparticles of mitoxantrone for local injection against breast cancer and its lymphnode metastases. Eur J Pharm Sci., 2006; 28: 86-95.

64. Wong HL, Rauth AM, Bendayan R. A new polymer-lipid hybrid nanoparticle system increases cytotoxicity of doxorubicin against multidrug-resistant human breast cancer cells. Pharm Res., 2006; 23: 1574-85.

65. Pandey R, Sharma S, Khuller GK. Oral SLN Based antitubercular chemotherapy. Tuberculosis (Edinb)., 2005; 85: 415-20.

66. Dvorak HF, Wagy AJ, Dvorak JT, Dvorak AM. Stealth liposomes. J Pathol, 1998; 133: 95-108.

67. Wang Y, Wu W. In situ evading of phagocytic uptake of stealth solid lipid nanoparticles by mouse peritoneal macrophages. Drug Deliv, 2006; 13: 189-92.